Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV zanamivir pharmacokinetics and safety in neonates and infants under 6 months with complicated influenza
NL-OMON50842Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanamivir in influenza, sponsored by GSK. Primary endpoints: Area under the serum concentration-time curve, Maximum serum concentration and 2 more. Planned start Jan 2021; status: withdrawn.
02
Drugs
zanamivir
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON50842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50842.